JAK抑制剂治疗类风湿关节炎感染风险的系统综述与荟萃分析
结果显示严重感染绝对发生率低,但带状疱疹发生率高于预期人群水平,巴瑞替尼组带状疱疹风险显著高于安慰剂。
要点
- 三种JAK抑制剂严重感染发生率均较低,与安慰剂相比无显著差异。
- 带状疱疹发生率总体高于预期人群水平(3.23/100患者年)。
- 巴瑞替尼组带状疱疹风险显著高于安慰剂(IRR 2.86)。
核心结论
- JAK抑制剂治疗类风湿关节炎的严重感染绝对发生率低,但带状疱疹发生率高于预期人群水平。
- 巴瑞替尼组带状疱疹风险显著高于安慰剂,但药物间间接比较未显示显著差异。
研究设计与样本
- 系统文献综述与荟萃分析,纳入II期和III期随机对照试验。
- 采用符合方案分析,计算每100患者年的粗发生率,并用荟萃合成方法比较药物与安慰剂的发病率比(IRR)。
主要发现
- 严重感染发生率:托法替布1.97(95%CI 1.41,2.68)、巴瑞替尼3.16(95%CI 2.07,4.63)、乌帕替尼3.02(95%CI 0.98,7.04)/100患者年。
- 严重感染IRR:托法替布1.22(95%CI 0.60,2.45)、巴瑞替尼0.80(95%CI 0.46,1.38)、乌帕替尼1.14(95%CI 0.24,5.43),均无统计学显著性。
- 带状疱疹发生率:托法替布2.51(95%CI 1.87,3.30)、巴瑞替尼3.16(95%CI 2.07,4.63)、乌帕替尼2.41(95%CI 0.66,6.18)/100患者年。
- 带状疱疹IRR:巴瑞替尼2.86(95%CI 1.26,6.50)显著;托法替布1.38(95%CI 0.66,2.88)和乌帕替尼0.78(95%CI 0.19,3.22)不显著。
- 排除带状疱疹的机会性感染过于罕见,无法提供有意义的发病率。
关键数值与推荐
- 托法替布剂量为5 mg每日两次,巴瑞替尼4 mg每日一次,乌帕替尼15 mg每日一次。
- 预期人群带状疱疹发生率为3.23/100患者年。
临床怎么用
- 临床使用JAK抑制剂时应关注带状疱疹风险,尤其是巴瑞替尼治疗者。
- 严重感染风险总体较低,但仍需个体化评估。
局限性
- 机会性感染(除带状疱疹外)过于罕见,无法提供有意义的发病率数据。
- 药物间比较为间接比较,未显示显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the risk of serious infection (SI) and herpes zoster (HZ) in rheumatoid arthritis patients receiving JAK inhibitors. METHODS: We conducted a systematic literature review and meta-analysis of phase II and III randomized controlled trials of tofacitinib (5 mg bid), baricitinib (4 mg od) and upadacitinib (15 mg od). Patient-exposure years were calculated. A per-protocol analysis was applied, incorporating follow-up time from patients randomized to placebo who cross into the treatment arm. Pooled incidence rates per 100 person-years of SI and HZ were calculated. Incidence rate ratios (IRRs) of drug vs placebo were compared using a meta-synthesis approach. RESULTS: Twenty-one studies were included in the meta-analysis; 11 tofacitinib (5888 patients), six baricitinib (3520 patients) and four upadacitinib studies (1736 patients). For SI, the incidence rates were 1.97 (95% CI: 1.41, 2.68), 3.16 (95% CI: 2.07, 4.63) and 3.02 (95% CI: 0.98, 7.04), respectively. The IRRs comparing treatment arm to placebo were statistically non-significant: 1.22 (95% CI: 0.60, 2.45), 0.80 (95% CI: 0.46, 1.38) and 1.14 (95% CI: 0.24, 5.43), respectively. For HZ, the incidence rates were 2.51 (95% CI: 1.87, 3.30), 3.16 (95% CI: 2.07, 4.63) and 2.41 (95% CI: 0.66, 6.18), respectively. The IRR of HZ comparing baricitinib with placebo was 2.86 (95% CI: 1.26, 6.50). Non-significant IRRs were seen with tofacitinib and upadacitinib: 1.38 (95% CI: 0.66, 2.88) and 0.78 (95% CI: 0.19, 3.22), respectively. Indicator opportunistic infections excluding HZ were too rare to provide meaningful incidence rates. CONCLUSION: The absolute SI rates were low. However across the JAK inhibitors, the incidence of HZ is higher than expected for the population (3.23 per 100 patient-years). While the risk was numerically greatest with baricitinib, indirect comparisons between the drugs did not demonstrate any significant difference in risk. SYSTEMATIC REVIEW REGISTRATION NUMBER: Prospero 2017 CRD4201707879.
引用
- Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019. PMID: 30982883. doi:10.1093/rheumatology/kez087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。